Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Veronica Venafra

Showing results (1-10 of 9) with videos related to

Pageof 1
Sort By:
NPJ Systems Biology and Applications|August 23, 2024
SignalingProfiler 2.0 a network-based approach to bridge multi-omics data to phenotypic hallmarksVeronica Venafra, Francesca Sacco, Livia Perfetto
Bioinformatics (Oxford, England)|February 5, 2025
NetworkCommons: bridging data, knowledge, and methods to build and evaluate context-specific biological networksVictor Paton, Denes Türei, Olga Ivanova, et al.
Iscience|May 25, 2026
Kinase inhibition rewires the HLA-I immunopeptidome in chronic myeloid leukemiaVeronica Venafra, Maria Wahle, Giorgia Massacci, et al.
Neurobiology of Disease|August 3, 2024
Stage-dependent phosphoproteome remodeling of Parkinson's disease blood cellsGiorgia Massacci, Veronica Venafra, Maximilian Zwiebel, et al.
Molecular Systems Biology|October 10, 2025
PatientProfiler: building patient-specific signaling models from proteogenomic dataVeronica Lombardi, Lorenzo Di Rocco, Eleonora Meo, et al.
Leukemia|December 12, 2022
A key role of the WEE1-CDK1 axis in mediating TKI-therapy resistance in FLT3-ITD positive acute myeloid leukemia patientsGiorgia Massacci, Veronica Venafra, Sara Latini, et al.
Cell Communication and Signaling : CCS|April 11, 2025
A network-based approach to overcome BCR::ABL1-independent resistance in chronic myeloid leukemiaValeria Bica, Veronica Venafra, Giorgia Massacci, et al.
Elife|April 2, 2024
Unveiling the signaling network of FLT3-ITD AML improves drug sensitivity predictionSara Latini, Veronica Venafra, Giorgia Massacci, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 20, 2024
Phase I Trial of Viral Vector-Based Personalized Vaccination Elicits Robust Neoantigen-Specific Antitumor T-Cell ResponsesAnna Morena D'Alise, Guido Leoni, Gabriella Cotugno, et al.
Pageof 1

Showing results (1-10 of 9) with videos related to

Sort By:
Pageof 1
NPJ Systems Biology and Applications|August 23, 2024
SignalingProfiler 2.0 a network-based approach to bridge multi-omics data to phenotypic hallmarksVeronica Venafra, Francesca Sacco, Livia Perfetto
Bioinformatics (Oxford, England)|February 5, 2025
NetworkCommons: bridging data, knowledge, and methods to build and evaluate context-specific biological networksVictor Paton, Denes Türei, Olga Ivanova, et al.
Iscience|May 25, 2026
Kinase inhibition rewires the HLA-I immunopeptidome in chronic myeloid leukemiaVeronica Venafra, Maria Wahle, Giorgia Massacci, et al.
Neurobiology of Disease|August 3, 2024
Stage-dependent phosphoproteome remodeling of Parkinson's disease blood cellsGiorgia Massacci, Veronica Venafra, Maximilian Zwiebel, et al.
Molecular Systems Biology|October 10, 2025
PatientProfiler: building patient-specific signaling models from proteogenomic dataVeronica Lombardi, Lorenzo Di Rocco, Eleonora Meo, et al.
Leukemia|December 12, 2022
A key role of the WEE1-CDK1 axis in mediating TKI-therapy resistance in FLT3-ITD positive acute myeloid leukemia patientsGiorgia Massacci, Veronica Venafra, Sara Latini, et al.
Cell Communication and Signaling : CCS|April 11, 2025
A network-based approach to overcome BCR::ABL1-independent resistance in chronic myeloid leukemiaValeria Bica, Veronica Venafra, Giorgia Massacci, et al.
Elife|April 2, 2024
Unveiling the signaling network of FLT3-ITD AML improves drug sensitivity predictionSara Latini, Veronica Venafra, Giorgia Massacci, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 20, 2024
Phase I Trial of Viral Vector-Based Personalized Vaccination Elicits Robust Neoantigen-Specific Antitumor T-Cell ResponsesAnna Morena D'Alise, Guido Leoni, Gabriella Cotugno, et al.
Pageof 1